GKV Capital Management’s Thermo Fisher Scientific TMO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$2.21M Sell
4,415
-40
-0.9% -$19.2K 0.71% 43
2026
Q1
$2.19M Sell
4,455
-616
-12% -$334K 0.82% 38
2025
Q4
$2.94M Sell
5,071
-10
-0.2% -$5.66K 1.1% 25
2025
Q3
$2.46M Sell
5,081
-250
-5% -$116K 0.97% 28
2025
Q2
$2.16M Sell
5,331
-1,285
-19% -$537K 0.96% 26
2025
Q1
$3.29M Sell
6,616
-400
-6% -$217K 1.64% 18
2024
Q4
$3.65M Buy
+7,016
New +$3.86M 1.49% 21

Other funds holding TMO

GKV Capital Management's TMO Position: Q2 2026 in Review

GKV Capital Management reduced its Thermo Fisher Scientific (TMO) stake by 0.9% in Q2 2026, selling an estimated $19.2K and leaving 4,415 shares worth $2.21M. The position accounts for 0.71% of the portfolio, ranked #43.

GKV Capital Management first reported a position in TMO in Q4 2024 and has held it in 7 quarters since. The position peaked at $3.65M in Q4 2024. 1,231 funds tracked by Wall St. Rank hold TMO as of Q2 2026.

  • GKV Capital Management held 4,415 shares of Thermo Fisher Scientific worth $2.21M as of Q2 2026.
  • GKV Capital Management sold 40 Thermo Fisher Scientific shares in Q2 2026, an estimated $19.2K.
  • Thermo Fisher Scientific made up 0.71% of GKV Capital Management's portfolio in Q2 2026, its #43 holding.
  • GKV Capital Management first reported a position in Thermo Fisher Scientific in Q4 2024 and has held it in 7 quarters since.
  • GKV Capital Management's Thermo Fisher Scientific position peaked at $3.65M in Q4 2024.
  • 1,231 funds tracked by Wall St. Rank held Thermo Fisher Scientific as of Q2 2026.

Based on GKV Capital Management's 13F filing for Q2 2026, filed 23 Jul 2026.